Holen Sie sich die Stockscreener-App
4.425
0.11%
0.005
Vorhandelsmarkt:
4.44
0.015
+0.34%
Schlusskurs vom Vortag:
$4.42
Offen:
$4.39
24-Stunden-Volumen:
2.30M
Relative Volume:
0.44
Marktkapitalisierung:
$1.06B
Einnahmen:
$251.85M
Nettoeinkommen (Verlust:
$-72.58M
KGV:
-14.12
EPS:
-0.3134
Netto-Cashflow:
$-63.80M
1W Leistung:
-1.67%
1M Leistung:
+24.30%
6M Leistung:
-12.38%
1J Leistung:
-22.37%
1-Tages-Spanne:
$4.32
$4.44
1-Wochen-Bereich:
$4.32
$4.69
52-Wochen-Spanne:
$3.21
$7.18
Ardelyx Inc Stock (ARDX) Company Profile
Firmenname
Ardelyx Inc
Sektor
Branche
Telefon
510-745-7047
Adresse
34175 ARDENWOOD BLVD., FREMONT, CA
Vergleichen Sie ARDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
4.425 | 1.08B | 251.85M | -72.58M | -63.80M | -0.3134 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-02 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-03-07 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2025-03-04 | Eingeleitet | BTIG Research | Buy |
| 2024-11-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-18 | Eingeleitet | Raymond James | Strong Buy |
| 2023-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-25 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-11-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | Herabstufung | Jefferies | Buy → Hold |
| 2021-07-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-23 | Eingeleitet | Wedbush | Outperform |
| 2021-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-20 | Fortgesetzt | Citigroup | Buy |
| 2020-02-18 | Fortgesetzt | Jefferies | Buy |
| 2020-02-12 | Eingeleitet | Citigroup | Buy |
| 2020-02-10 | Eingeleitet | Cowen | Outperform |
| 2019-04-08 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-24 | Eingeleitet | Jefferies | Buy |
| 2018-03-19 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-11-29 | Bestätigt | Citigroup | Buy |
| 2017-11-22 | Bestätigt | Ladenburg Thalmann | Buy |
| 2017-10-17 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-03-31 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-03-09 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2016-03-03 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Ardelyx Inc Aktie (ARDX) Neueste Nachrichten
What drives Ardelyx Inc. stock priceUnstoppable profit momentum - Autocar Professional
Is Ardelyx Inc. a good long term investmentConsistent triple returns - jammulinksnews.com
What analysts say about Ardelyx Inc. stockFree Capital Allocation Plans - jammulinksnews.com
11 Best American Penny Stocks to Buy According to Analysts - Insider Monkey
5 stocks with growth potential: SOUN, JBL, MNTN, ARDX, RCEL - Markets.com
Ardelyx Announces Q2 2025 Financial Results Conference Call - AInvest
Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025 - The Globe and Mail
Ardelyx Sets Q2 Earnings Date: Key Financial Updates Expected from Biopharma Innovator - Stock Titan
Ardelyx Inc. Stock Analysis and ForecastAccelerated wealth expansion - Autocar Professional
Lobbying Update: $540,000 of ARDELYX INC. lobbying was just disclosed - Quiver Quantitative
Wedbush Issues Negative Outlook for Ardelyx Earnings - MarketBeat
This Small-Cap Stock Could 10x By 2030, But It’s Not For The Faint Of Heart - Barchart.com
Wedbush Raises Price Target on Ardelyx to $13 From $11, Keeps Outperform Rating - MarketScreener
Long Term Trading Analysis for (ARDX) - news.stocktradersdaily.com
Jefferies Maintains a Buy Rating on Ardelyx (ARDX) With an $8 Price Target - MSN
Lobbying Update: $50,000 of ARDELYX INC. lobbying was just disclosed - Quiver Quantitative
There's No Escaping Ardelyx, Inc.'s (NASDAQ:ARDX) Muted Revenues Despite A 26% Share Price Rise - simplywall.st
Ardelyx Faces An Uphill Battle Despite Oral Arguments Set In XPHOZAH Appeal (NASDAQ:ARDX) - Seeking Alpha
Cantor Fitzgerald reiterates Overweight rating on Ardelyx stock - Investing.com
Cantor Fitzgerald reiterates Overweight rating on Ardelyx stock By Investing.com - Investing.com Nigeria
Ardelyx (ARDX) Appoints New Chief Business and HR Officers - MSN
Leerink Partners Maintains a Buy Rating on Ardelyx (ARDX) With a $10 PT - MSN
Levi & Korsinsky Reminds Ardelyx, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024 – ARDX - ACCESS Newswire
Ardelyx amends loan agreement to draw $50 million and secures future options - Investing.com
Ardelyx spike attributed to Xphozah legal update - MSN
Ardelyx stock spike attributed to Xphozah update (ARDX:NASDAQ) - Seeking Alpha
(ARDX) Trading Signals - news.stocktradersdaily.com
A biopharma bolsters patient centricity and trial diversity goals through newly created role - Yahoo Finance
10 Best Healthcare Penny Stocks to Buy According to Analysts - Insider Monkey
Two Beaten-Down Biotech Stocks See Big Insider Buys - Barron's
H.C. Wainwright Initiates Coverage of Ardelyx (ARDX) Stock, Gives Buy - MSN
13 Best Long-Term Penny Stocks to Buy According to Analysts - Insider Monkey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc.ARDX - PR Newswire
Director David Mott Acquires 200,000 Shares of Ardelyx Inc (ARDX) - GuruFocus
Ardelyx Stockholders Approve Equity Plan Amendment - TipRanks
Finanzdaten der Ardelyx Inc-Aktie (ARDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):